{"entity":{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","aka":["Huiyu Pharma","四川汇宇制药"],"tldr":"Sichuan Huiyu Pharmaceutical is a China-based pharmaceutical company that leads 5 cancer trials in OnCo, testing the in-house candidates HY0001a, HY05350, HY07121, HYP-6589 and HYP-2090 in advanced solid tumours.","summary":"Sichuan Huiyu Pharmaceutical is a research-driven pharmaceutical company that develops, manufactures and sells anti-tumour and injectable medicines for global markets, with a growing pipeline of in-house innovative drugs and a UK subsidiary, Seacross Pharma. It is listed on the Shanghai Stock Exchange STAR Market. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo: NCT07069062 (phase 1/2, A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced So...), NCT07083323 (phase 1/2, A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors), NCT06712680 (phase 1/2, A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Com...), NCT06639256 (phase 1/2, Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With A...) and NCT06243354 (phase 1/2, Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS M...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.huiyupharma.com/"},{"label":"ClinicalTrials.gov: trials led by Sichuan Huiyu Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Sichuan%20Huiyu%20Pharmaceutical%20Co.%2C%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07069062","nct07083323","nct06712680","nct06639256","nct06243354"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Neijiang, Sichuan","country":"CN","companyType":"pharma","website":"https://www.huiyupharma.com/","ticker":"SSE:688553","founded":2010,"stage":"public","investors":[],"funding":[]},"route":"/companies/sichuan-huiyu-pharmaceutical/","neighbours":{"trial":[{"id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/"},{"id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/"},{"id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/"},{"id":"nct06639256","kind":"trial","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","route":"/trials/nct06639256/"},{"id":"nct06243354","kind":"trial","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","route":"/trials/nct06243354/"}]}}